Amphastar Pharmaceuticals (AMPH)

• Market cap: $1.84B
• 1 day: -2.17%
• 5 days: -6.13%
• 1 month: -14.27%
• 3 months: -19.24%
• 6 months: -6.29%
• Year to date: -38.56%
• 1 year: -38.78%
• 5 years: 94.86%
• 10 years: 225.98%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Amphastar Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.

Employees: 1,761

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

248% more call options, than puts

Call options by funds: $3.91M | Put options by funds: $1.12M

50% more funds holding in top 10

Funds holding in top 10: 2 [Q2] → 3 (+1) [Q3]

24% more first-time investments, than exits

New positions opened: 42 | Existing positions closed: 34

22% more capital invested

Capital invested by funds: $1.4B [Q2] → $1.71B (+$313M) [Q3]

3% more funds holding

Funds holding: 267 [Q2] → 275 (+8) [Q3]

1.01% more ownership

Funds ownership: 71.59% [Q2] → 72.6% (+1.01%) [Q3]

4% more repeat investments, than reductions

Existing positions increased: 97 | Existing positions reduced: 93

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $55 44% upside
• Avg. target: $55 44% upside
• High target: $55 44% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Wells Fargo Joe Quatrochi 0% 1-year accuracy 0 / 5 met price target

44% upside $55

Overweight Initiated

22 Nov 2024